Letter to the Editor Regarding “Treatment Persistence Among Anti–Tumor Necrosis Factor–experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti–Tumor Necrosis Factor Agent”

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-10-01 DOI:10.1016/j.clinthera.2025.06.009

Joaquín Borrás-Blasco PhD , Alejandro Valcuende-Rosique PhD , Silvia Cornejo-Uixeda PharmD

引用次数: 0

查看原文本刊更多论文

关于“抗肿瘤坏死因子治疗经验丰富的溃疡性结肠炎患者的治疗持久性切换到具有不同作用模式的生物制剂或循环使用另一种抗肿瘤坏死因子药物”的致编辑的信

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.